Stella Diagnostics (Stella Diagnostics) Institutional Ownership : 0.00% (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Stella Diagnostics's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Stella Diagnostics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Stella Diagnostics's Float Percentage Of Total Shares Outstanding is 0.00%.

Stella Diagnostics Institutional Ownership Historical Data

The historical data trend for Stella Diagnostics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Institutional Ownership Chart

Stella Diagnostics Annual Data

Trend

Institutional Ownership

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Institutional Ownership	-	-

Stella Diagnostics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.